David Ahn, MD
@ahncall
Believer, Endocrinologist, Writer, Co-Founder. Program Director of Allen Diabetes Center @HoagHealth. I love talking digital health, diabetes, and sports.
ID: 292187017
http://hoag.org 03-05-2011 07:34:25
1,1K Tweet
1,1K Takipçi
1,1K Takip Edilen
Discontinuing glucagon‐like peptide‐1 receptor agonists World Obesity proportion of weight regained was proportional to the amount originally lost Wiley Online Library onlinelibrary.wiley.com/doi/10.1111/ob…
Really excited to partake in this debate as I go toe to toe with Diana Isaacs, PharmD, BC-ADM, CDCES on the pros/cons of OTC CGM’s like #stelo and #lingo. I’m taking the con perspective, so it should be fun playing the villain! 😅 #ADASciSessions
Debate Fri 6.20 1245pm at #ADASciSessions OTC CGM: Data 4 all or a disaster waiting to happen. David Ahn, MD prepare to be taken down! #CGM4all
TING (70-140 mg/dL) and TIR (70-180 mg/dL) are greater indicators for diabetic complications at #ADA2025 by Tadej Battelino Time to retire HbA1c and use CGM metrics for follow up.
If it pans out, cheaper obesity meds are a win for patients, esp since Medicare has been so hard to get coverage! But what about the Medicare Prescription Drug, Improvement, Modernization Act of 2003, which excludes AOM’s from Part D coverage? Beverly G. Tchang, MD Michael Albert, MD